{"id":54425,"date":"2023-03-02T14:04:38","date_gmt":"2023-03-02T13:04:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/"},"modified":"2023-03-02T14:04:38","modified_gmt":"2023-03-02T13:04:38","slug":"koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/","title":{"rendered":"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–#biotech<\/a>—Koneksa<\/a>, the evidence-based digital biomarkers company, announced today an extended partnership with SSI Strategy<\/a>, a life sciences consulting firm, that will provide both organizations with expanded client service offerings to accelerate and scale the adoption of evidence-based digital biomarkers in clinical trials.\n<\/p>\n

<\/a><\/p>\n

\nKoneksa’s digital biomarker solutions\u00a0include\u00a0an industry-leading platform that\u00a0gives\u00a0research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual\u2019s health.\n<\/p>\n

\nAs part of the partnership, SSI will expand Koneksa\u2019s medical strategy division, especially in translational and clinical drug development. This collaboration will offer existing clients of both organizations a streamlined relationship offering the industry\u2019s best scientific, technical, and delivery expertise across all phases of the clinical trial and product lifecycle. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development. SSI clients gain access to Koneksa’s industry-leading expertise in developing and employing evidence-based digital biomarkers.\n<\/p>\n

\n\u201cThis synergistic partnership is a combination of resources, talent and expertise across two leading science-based organizations with a mission of optimizing and accelerating therapies for patients in need, through greater adoption of digital biomarkers in clinical studies,\u201d said Vik Shah, President and COO of Koneksa. \u201cThis expanded partnership is in response to the growing interest from life sciences companies to have an in-house digital biomarker solution, and SSI will enable us to rapidly scale our medical and scientific functions to meet this demand. SSI will also be able to provide clients with leading expertise in digital biomarkers from the Koneksa team, to accelerate clinical trials and bring new life-saving therapies to patients faster.\u201d\n<\/p>\n

\n\u201cKoneksa\u2019s digital biomarker solutions capture actionable measures that will enable therapeutic developers to efficiently address pre- and post-market evidence requirements at much earlier stages of development,\u201d said Doug Locke, CEO of SSI Strategy. \u201cWe particularly see the collaboration as mutually beneficial to many of our rare-disease client partners, in alignment with our growing digital health practice.\u201d\n<\/p>\n

\n\u201cWe look for similar customer-oriented ethos and patient-centric mindsets in our partnerships,\u201d said Kim Kushner, Chief Business Officer, SSI Strategy. \u201cOur engagement over the past year in scaling and expanding Koneksa\u2019s medical function, under the leadership of Koneksa Chief Medical Officer Dr. John Wagner, has confirmed that our interests are highly aligned, and we look forward to this next phase of growth.\u201d\n<\/p>\n

\nAbout Koneksa<\/b>\n<\/p>\n

\nKoneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Our evidence-based biomarker solutions enable efficient clinical trial designs to help innovative therapies reach patients faster. Koneksa aims to revolutionize treatment effect detection in clinical research and improve patient outcomes. Learn more at koneksahealth.com.\n<\/p>\n

\nAbout SSI Strategy<\/b>\n<\/p>\n

\nSSI Strategy combines business acumen, medical, clinical, translational and pharmacovigilance domain expertise, combined with operating experience to provide unparalleled support to our clients. Our staff of ex-Chief Medical Officers and former Heads of Medical Affairs, Clinical Development and Safety will work to ensure the right balance of medical and business focus to drive optimal outcomes for clients. SSI Strategy is headquartered in Parsippany, NJ, with offices in Boston, London, New York, and San Francisco. For more information on SSI Strategy, please visit www.ssistrategy.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>\n<\/p>\n

\nKimberly Ha
\n
KKH Advisors
\n
917-291-5744
\n
kimberly.ha@kkhadvisors.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–#biotech—Koneksa, the evidence-based digital biomarkers company, announced today an extended partnership with SSI Strategy, a life sciences consulting firm, that will provide both organizations with expanded client service offerings to accelerate and scale the adoption of evidence-based digital biomarkers in clinical trials. Koneksa’s digital biomarker solutions\u00a0include\u00a0an industry-leading platform that\u00a0gives\u00a0research sponsors and clinical sites … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54425","6":"format-standard","7":"category-industry"},"yoast_head":"\nKoneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK–(BUSINESS WIRE)–#biotech—Koneksa, the evidence-based digital biomarkers company, announced today an extended partnership with SSI Strategy, a life sciences consulting firm, that will provide both organizations with expanded client service offerings to accelerate and scale the adoption of evidence-based digital biomarkers in clinical trials. Koneksa’s digital biomarker solutions\u00a0include\u00a0an industry-leading platform that\u00a0gives\u00a0research sponsors and clinical sites ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-02T13:04:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230302005148\/en\/1727712\/21\/Koneksa_Logo_Print.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials\",\"datePublished\":\"2023-03-02T13:04:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/\"},\"wordCount\":585,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005148\\\/en\\\/1727712\\\/21\\\/Koneksa_Logo_Print.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/\",\"name\":\"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005148\\\/en\\\/1727712\\\/21\\\/Koneksa_Logo_Print.jpg\",\"datePublished\":\"2023-03-02T13:04:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005148\\\/en\\\/1727712\\\/21\\\/Koneksa_Logo_Print.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005148\\\/en\\\/1727712\\\/21\\\/Koneksa_Logo_Print.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials - Pharma Trend","og_description":"NEW YORK–(BUSINESS WIRE)–#biotech—Koneksa, the evidence-based digital biomarkers company, announced today an extended partnership with SSI Strategy, a life sciences consulting firm, that will provide both organizations with expanded client service offerings to accelerate and scale the adoption of evidence-based digital biomarkers in clinical trials. Koneksa’s digital biomarker solutions\u00a0include\u00a0an industry-leading platform that\u00a0gives\u00a0research sponsors and clinical sites ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-02T13:04:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230302005148\/en\/1727712\/21\/Koneksa_Logo_Print.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials","datePublished":"2023-03-02T13:04:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/"},"wordCount":585,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230302005148\/en\/1727712\/21\/Koneksa_Logo_Print.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/","url":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/","name":"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230302005148\/en\/1727712\/21\/Koneksa_Logo_Print.jpg","datePublished":"2023-03-02T13:04:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230302005148\/en\/1727712\/21\/Koneksa_Logo_Print.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230302005148\/en\/1727712\/21\/Koneksa_Logo_Print.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/koneksa-announces-expanded-partnership-with-ssi-strategy-to-scale-the-adoption-of-digital-biomarkers-in-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54425"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54425\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}